Free Trial
OTCMKTS:ARTH

Arch Therapeutics 5/23/2023 Earnings Report

Arch Therapeutics logo
$0.16 -0.04 (-19.60%)
As of 02:23 PM Eastern

Arch Therapeutics EPS Results

Actual EPS
$0.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Arch Therapeutics Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Arch Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Arch Therapeutics' next earnings date is estimated for Friday, April 25, 2025, based on past reporting schedules.

Conference Call Resources

Arch Therapeutics Earnings Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
Arch Therapeutics, Inc. (ARTH)
See More Arch Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arch Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arch Therapeutics and other key companies, straight to your email.

About Arch Therapeutics

Arch Therapeutics (OTCMKTS:ARTH), together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

View Arch Therapeutics Profile

More Earnings Resources from MarketBeat